Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/p/DSk24Hkj3it/The advent of CAR-T cell therapy has revolutionized the oncologic management of blood cell cancers that readily display their tumor-specific antigens.  Solid cancerous tumors that grow in major organs including the breast, lungs, and the liver are so closely packed that their tumor-specific markers are hidden preventing the modified T killer cells from attacking them. For this reason CAR-T strategies have been ineffective.University of Southern California bioengineers have a solution.  Using focused ultrasound, they are able to literally shake and prime solid tumor cells to produce and reveal a common tumor marker CD19 that CAR-T killer cells can hone in on and destroy their target. The ultrasound can be precisely aimed in an effort to restrict the immunotherapeutic effect to a localized zone. The researchers conducted studies on tumor organoids and mouse models. This ultrasonic trigger led to strong, localized immune attacks even when only 10–15% of tumor cel